Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
最近の投稿
IDF strikes Tehran command centers, weapon production sites- Must-See Attractions in Australia
- 21 Things You Ought to Never Tell Your Childless Companion
- The Artemis II launch is tonight. Here's how to watch it live.
- Tens of thousands protest as far-right AfD forms new youth group
- Watch interstellar comet 3I/ATLAS speed away from the sun in free telescope livestream on Nov. 16
- She just became the first wheelchair user to travel to space
- Highlight Correlation of Microsoft Surface Book and Surface Genius Workstations for Determination
- 5 Christmas movies to stream for less with this Paramount+ Black Friday deal
